Medco Health Solutions

Goldman Sachs commented on market volatility. In a research report published today, Goldman named companies it believes are best investment in these volatile times. In the report, Goldman states, “In the face of a flattish S&P 500 we encourage investors to utilize straddles as a method to...

Earnings season ramps up this week with quarterly reports due from the likes of tech companies such as IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT), big banks such as Wells Fargo (NYSE: WFC) and Bank of America (NYSE: BAC), and consumer goods giants such as PepsiCo (NYSE: PEP) and Johnson &...

According to Citi, Medco Health Solutions (NYSE: MHS) Buy rating is maintained. Citi said that it recently attended the Drug Information Association (DIA) annual conference in Chicago and visited with the United BioSource (UBC) segment of Medco. “We maintain our Buy rating on MHS shares given the...

J.P. Morgan is out with its report today on Medco Health Solutions (NYSE: MHS), lowering its PT from $78 to $73. In a note to clients, J.P. Morgan writes, "We maintain our Overweight rating on MHS following the loss of the FEP mail contract. While we view the 9% decline as an overreaction, shares...

JP Morgan has lowered the price target on Medco Health Solutions (NYSE: MHS) from $78 to $73 and maintains its Overweight rating.

According to J.P. Morgan, Medco Health Solutions (NYSE: MHS) $78 target price represents 34% upside from current levels. J.P. Morgan said that it believes the risk reward profile around Medco has improved substantially, and are reiterating the Overweight rating, noting that its $78 December 2011...

Momentum in equities should parlay into solid performance for larger cap healthcare names such as pharmacy benefit managers, labs and hospitals. In the report, Jefferies writes, “We continue to believe that [Quest Diagnostics] DGX, [Express Scripts, Inc.] ESRX, [Medco Health Solutions, Inc.] MHS (...

J.P. Morgan has reported a maintained Overweight Rating On Medco Health Solutions Inc. (NYSE: MSH). According to the report, “We maintain our OW rating on MHS. We believe downside could be limited to roughly $50, which we arrive at by applying a conservative 15% discount to the current ESRX...

In a report published by Deutsche Bank, Medco Health Solutions (NYSE: MHS) is downgraded to Hold given the uncertainty post CalPERS. Deutsche Bank said that late Last Wednesday, CalPERS, the largest pension fund manager in the US announced that it was terminating its negotiations with MHS...

Deutsche Bank has downgraded Medco Health Solutions (NYSE: MHS) from Buy to Hold and has lowered the price target from $77 to $55.

Morgan Stanley is out with its report today on Medco Health Solutions (NYSE: MHS), maintaining Overweight. In a note to clients, Morgan Stanley writes, "Framing a bear case scenario, if MHS were to retain only 92% of its ~$17 billion in revenues up for renewal (mirroring CVS' renewal rates in the...

Jefferies has published a report regarding Medco Health Solutions' (NYSE: MHS) Rating after the loss of the CalPERS contract. In the report Jefferies writes, "We believe that the loss of MHS's CalPERS contract will adversely impact FY12 EPS by ~0.07, a minuscule amount relative to MHS's projected...

Medco Health Solutions (NYSE: MHS) posted an in-line Q4 and did not raise guidance, Jefferies reports. “Expect stock to trade flat or down on this news,” Jefferies writes. “MHS reported in-line adjusted 4Q10 EPS of $0.94 on revenues of $16.9B, EBITDA of $786.7MM and EBITDA/adjusted claim of $3.22 (...

Argus increases its price target on: Exxon Mobil (NYSE: XOM) from $76 to $85. Medco Health Solutions (NYSE: MHS) from $60 to $69. Chipotle Mexican Grill (NYSE: CMG) from $238 to $270.